/C O R R E C T I O N -- Aethlon Medical, Inc./

In the news release, Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023, issued 06-Feb-2023 by Aethlon Medical, Inc. over PR Newswire, we are advised by the company that in the 1st and 2nd paragraphs, both mentions of "February 6, 2023" should read "February 13, 2023" as originally issued inadvertently. The complete, corrected release follows:

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023

/PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 13, 2023.

Management will host a conference call on Monday, February 13, 2023 at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10175587/f5e2dfab9b. Please note that registered participants will receive their dial in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling: 
PARTICIPANT DIAL IN (TOLL FREE):          1-844-836-8741
All callers should ask for the Aethlon Medical, Inc. conference call. 

A replay of the call will be available approximately one hour after the end of the call through March 13, 2023. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 4716809.

About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, as its lead technology. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology.  This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.

The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc. 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC

Cision View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-february-13-2023-301738635.html

SOURCE Aethlon Medical, Inc.